Serina Therapeutics, Inc.
SER · XNYSCIK 1708599fmd_16FNQF3122WF47Q8FZY3BJGPBSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 2 | 0 | 0 | 0 | 3 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – |
| Gross profit | 1 | 1 | 1 | 0 | 0 | 0 | 0 | – | – |
| Research and development | 6 | 6 | 6 | 4 | 1 | 1 | 2 | 7 | 13 |
| Total operating expenses | 10 | (12) | 14 | 10 | 8 | 7 | 6 | 17 | 24 |
| Operating income | (7) | (11) | (13) | (10) | (8) | (7) | (3) | (17) | (24) |
| Interest expense | – | – | – | – | 1 | 3 | 1 | 1 | 0 |
| Other non-operating income (expense) | 0 | 4 | 0 | (0) | (1) | (4) | 8 | 6 | 5 |
| Income before taxes | – | (8) | (12) | (11) | 9 | 11 | 5 | (11) | (19) |
| Income tax expense | – | – | 0 | (0) | – | – | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (12) | 0 | (9) | (11) | 5 | (11) | (19) |
| Net income | (7) | (8) | (12) | (11) | (9) | (10) | 5 | (11) | (19) |
| Net income to common shareholders | – | – | – | 10 | 9 | – | 5 | (11) | (19) |